Nuwellis, Inc. · NASDAQ:NUWE
Nuwellis — Investor Presentation (August 2026)
25 slides from Nuwellis's investor presentation, Aug 26, 2026
Slide 1: Investor Presentation August 2026
August 2026 INVESTOR PRESENTATION NASDQ: NUWE
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward‐looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act, as amended regarding our plans, expectations, beliefs, estimates, goals and outlook for the
Slide 3: Investment Highlights
Investment Highlights 3 Best-in-class ultrafiltration technology Aquadex® is a clinically proven system for precise, predictable fluid removal reducing readmissions and improving outcomes Streamlined solution that is cost-effective, workflow-friendly, and backed by comprehensive clinical support Exp
Slide 4: Fluid Overload Drives Mortality and Hospitalizations
Fluid Overload Drives Mortality and Hospitalizations 4 Higher ICU Mortality Fluid overload is associated with significantly increased 90-day mortality in critically ill ICU patients2 Increased Pediatric Mortality Fluid overload is linked to substantially higher mortality in critically ill children3-
Slide 5: A $4.2B U.S. Clinical Addressable Market Opportunity
A $4.2B U.S. Clinical Addressable Market Opportunity 5 Nuwellis current platform and future products collectively address an enormous market opportunity across five segments Critical Care Inpatient HF Outpatient HF Pediatrics Fluid Monitoring Sources: See Appendix $900MMarket $1BMarket $770MMarket $
Slide 6: Our Solution: Aquadex
6 Our Solution Aquadex®A clinically proven therapy for precise, predictable fluid removal1 Low-volume ultrafiltration designed for critically ill patients Allows controlled fluid removal when diuretics fail Adopted in ICU, cardiac surgery, and pediatric critical care programs 1Pinney, S et. al., J A
Slide 7: Aquadex System: Predictable and Precise Fluid Removal
Aquadex System: Predictable and Precise Fluid Removal Filtered blood returns to the patient via the infusion line 5 Blood is taken from the patient via the withdrawal line using proprietary catheter technology 1 The blood is pushed through the filter by the blood pump (0-40 ml per minute) 2 The ultr
Slide 8: Aquadex System: High-Margin Recurring Revenue Model
Aquadex System: High-Margin Recurring Revenue Model 8 Flexible acquisition models: purchase, lease or rental Increasing utilization as adoption spreads One-time CapEx purchase Price point: high-value Single-use for every treatment High-margin Aquadex Console Capital Equipment Disposables Recurring R
Slide 9: Why Hospitals Are Adopting Precision Fluid Management
Why Hospitals Are Adopting Precision Fluid Management 9 Mortality Acute Kidney Injury Risk (AKI) Readmissions Pediatrics Fluid overload > 5% body-weight gain is associated with significantly higher mortality across ICU cohorts.1 Postoperative AKI drives higher mortality and longer ICU/PICU stays.2 I
Slide 10: Commercial Execution Demonstrating Broad-Based Growth
Commercial Execution Demonstrating Broad-Based Growth 10 Broad Clinical Coverage Pediatric - 29% growth* Pediatric Nephrology & Critical Care Critical Care – 28% growth* ICU/Intensivists & Cardiac Surgery Heart Failure – 27% growth* Heart failure Cardiology *H1 revenue growth YOY Complex Therapy Sal
Slide 11: Pediatric Adoption Validates Market Need
11 Providers are increasingly seeking out Aquadex for use with children, validating both the clinical demand and the growing commercial footprint in pediatric centers Expansion of Aquadex labelled weight indication to > 5kg to facilitate broader adoption Development of Vivian as the next-generation
Slide 12: Aquadex Pediatric Growth Expansion
Aquadex Pediatric Growth Expansion 12 Successfully completed FDA pre-submission meeting for proposed Aquadex label expansion to pediatric patients ≥5 kg Proposed expansion supported by: Established body of published pediatric clinical experience Real-world utilization at leading pediatric centers Gr
Slide 13: Critical Care: Addressing Fluid Overload Following Cardiac Surgery
Critical Care: Addressing Fluid Overload Following Cardiac Surgery 13 The ProblemCardiac surgery can require significant fluid administration, contributing to post-operative fluid overload1 1 DeVore A, et al. Curr Treat Opts Cardiovasc Med. 2014; 16(2):283. 2 Bundgaard-Nielsen M, et al. Acta Anaesth
Slide 14: Heart Failure: Breaking the Cycle of Fluid Overload and Readmission
Heart Failure: Breaking the Cycle of Fluid Overload and Readmission 14 The Problem Persistent congestion drives repeat hospitalization Aquadex Solution Precise, predictable fluid removal – for patients with fluid overload when diuretics are inadequate 60% Reduction in HF Events at 30 days – Adjustab
Slide 15: Expanding Beyond Fluid Removal into Critical Care Solutions
Expanding Beyond Fluid Removal into Critical Care Solutions 15 Current Commercial Engine Near-term Expansion Long-term Pediatric Upside Leveraging our ICU & pediatric commercial infrastructure to expand into adjacent monitoring and therapy markets ClarityPRIME Precision fluid removal platform deploy
Slide 16: R&D Expanding Aquadex Capabilities to Extend Platform Use
R&D Expanding Aquadex Capabilities to Extend Platform Use 16 SmartView Provides Real-time Insights Expanding Filtration Range Built For High Flow Multiple Filters For Critical Care Optimizes therapy and supports decisions Seamlessly integrated with EMR and hospital systems Simplifies workflows and i
Slide 17: Introducing Vivian
17 Introducing Vivian™Developing our dedicated pediatric solution Currently in development and supported by a $3M NIH grant. Ultra-low ECV (29–67 mL) for neonatal + small-child CRRT Engineered for patients as small as 2.5kg with unique Hematocrit and SVO2 sensor safety features Integrated UF, CVVH,
Slide 18: ClarityPRIME Expands Nuwellis into Smart Fluid Monitoring
ClarityPRIME* Systems Expands Nuwellis into Smart Fluid Monitoring 18 Addresses A Critical Need in Cardiac Surgery & Critical Care Enters a High-growth, Underpenetrated Market Fits Directly Into Our Existing Sales Channel Real-time urine output and electrolyte data are essential for early detection
Slide 19: Co-Promotion and Distribution Agreements for AtriAmp
Co-Promotion and Distribution Agreements withfor AtriAmp® Cardiac Rhythm Monitoring 19 Ability to expand revenue per customer by leveraging critical-care commercial infrastructure FDA cleared, sterile, single-patient-use device for adult and pediatric patients with temporary epicardial pacing wires
Slide 20: Strategy Drives Growth with Operating Discipline
Strategy Drives Growth with Operating Discipline Drive physician adoption within new and existing hospitals Expand label to pediatric patients > 5kg Enhance system with workflow improvements and data integration Recent acquisition extends cardiorenal platform Clarity PRIME targeted launch in 2027 Ab
Slide 21: Target Milestones
Target Milestones 21 Target Date Milestone Q3 2026 Publication of ULTRA-Peds data Q4 2026 FDA 510k submission for Pediatric indication expansion to 5kg (from 20kg) Q4 2026 Additional strategic partnership/distribution agreements H1 2027 Launch of SmartView for Aquadex H2 2027 Launch of expanded high
Slide 22: Nuwellis Leadership Team
Nuwellis Leadership Team 22 Over 200 years of combined experience in clinical practice and the medical device industry, including major tenures at J&J, Boston Scientific, Medtronic, and Abbott/St. Jude Medical Ryan Marthaler Vice President of Product Marketing and Business Development Betsy Riemensc
Slide 23: Financial Highlights
Financial Highlights 23 Capitalization as of August 10, 2026 Common Equivalents Common Stock 3,647,264 Preferred Stock* 5,859 Warrants (weighted avg. exercise price: $10.66) 2,102,300 Options (weighted avg. exercise price: $72.89) 1,722 Fully Diluted 5,757,145 H1 2026 Revenue Growth +20% YoY Q2 2026
Slide 24: Contact Details
Contact Details Investor & Media Relations: CORE IRYvonne Briggs ir@nuwellis.com Media Inquiries: CORE PRKati Waldenburg media@nuwellis.com
Slide 25: Appendix: Market Size Sources
Appendix Market Size Sources Heart Failure – Inpatient Incidence of HF: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494150/ Annual HF Hospitalizations: Costanzo MR, et al. J Am Coll Cardiol. 2017 May 16;69(19):2428-2445 Insufficient diuretic response: https://www.ahajournals.org/doi/10.1161/CIRCHE